Category Archives: Patent Opposition
Source: Business World The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral medicines, which are currently sold at very high prices Patient and healthcare aid groups, including I-MAK and Delhi Network of … Continue reading
By Rupali Mukherjee, The Times of India MUMBAI: Healthcare aid and patient groups have come together in patent courts to fight against “abusive strategies” of Big Pharma, to ensure access to affordable treatment in hepatitis C. The Initiative for Medicines, … Continue reading
Source: MSF Access Campaign New Delhi/New York, 14 February 2017–Five new challenges against patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. … Continue reading
The Indian Patent Office recently denied a patent for the drug Xtandi (Enzalutamide) by Japanese firm Astellas Pharma used in treatment of prostate cancer. This decision comes in the light of the pre-grant opposition filed by pharma companies BDR Pharma, drug … Continue reading
(Paris, October 5th 2016) European Patent Office (EPO) has taken its decision following Doctors of the World – Médecins du Monde (MdM) patent opposition on Gilead Sciences’ Sofosbuvir. MdM applauds EPO’s decision to revoke partially the patent.
Impact of data exclusivity in Ukraine on access to affordable generic version of sofosbuvir ( direct acting antiviral – DAA used for Hepatitis C treatment) Chronology of events/facts Pharmasset originally developed Sofosbuvir. Gilead Sciences acquired Pharmasset including its Hepatititis C compounds sofosbuvir for … Continue reading
By Vishakh Unnikrishnan, The CatchNews | May 14, 2016 Landing a blow to efforts to make vital drugs more affordable, the Indian Patent Office has granted the American pharmaceutical company Gilead a patent for sofosbuvir, which is used to treat … Continue reading